Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Completed1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

completed133%
recruiting133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038
completedphase_3

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

NCT01855750
unknownphase_2

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

NCT05200312

Clinical Trials (3)

Showing 3 of 3 trials
NCT06564038Phase 1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Recruiting
NCT01855750Phase 3

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed
NCT05200312Phase 2

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3